4-(环己基氨基)-1-丁烷磺酸 | 161308-34-5

• 物质功能分类: 有机原料 - 氨基化合物 - 环烷胺、芳香单胺、芳香多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4-(环己基氨基)-1-丁烷磺酸
• 英文名称: CABS
• 英文别名: 4-cyclohexylamino-1-butane sulfonic acid；4-(Cyclohexylamino)-1-butanesulfonic acid；4-(cyclohexylamino)butane-1-sulfonic acid
• CAS: 161308-34-5
• 化学式: C₁₀H₂₁NO₃S
• 分子量: 235.348
• InChiKey: XNPKNHHFCKSMRV-UHFFFAOYSA-N

物化性质

• 密度：
  1.17±0.1 g/cm3(Predicted)
• LogP：
  -2 at 20℃ and pH7-13
• 表面张力：
  71.31mN/m at 1g/L and 20℃

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  74.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• WGK Germany：
  3

制备方法与用途

CHES 和 CAPS 都具有较高的 pKa 值，在生物系统中有着相似的应用。

反应信息

• 作为产物：
  描述：

  环己胺 、 1,4-丁磺酸内酯 在 丙酮 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 生成 4-(环己基氨基)-1-丁烷磺酸
  参考文献：
  名称：

  METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES

  摘要：

  本发明涉及用于治疗或预防淀粉样蛋白相关疾病的方法、化合物、制药组合物和试剂盒。

  公开号：

  US20100113591A1

文献信息

• Methods and compositions for treating amyloid-related diseases
  申请人：Kong Xianqi

  公开号：US20060223855A1

  公开（公告）日：2006-10-05

  Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

  描述了用于治疗或预防与淀粉样蛋白相关疾病的方法、化合物、药物组合物和试剂盒。
• [EN] PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF<br/>[FR] PROCÉDÉS DE PRÉPARATION D'INHIBITEURS D'ACC ET FORMES SOLIDES CORRESPONDANTES
  申请人：GILEAD SCIENCES INC

  公开号：WO2018161022A1

  公开（公告）日：2018-09-07

  The present disclosure provides solid forms, including a salt or co-crystal, of Compound I which exhibits Acetyl-CoA carboxylase ("ACC") inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.

  本公开提供了化合物I的固体形式，包括盐或共晶，该化合物表现出乙酰辅酶A羧化酶（"ACC"）抑制活性，并可能在治疗ACC介导的疾病中有用。本文还提供了用于制备化合物I的过程或步骤，以及对所述过程或步骤有用的中间体。
• [EN] NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF<br/>[FR] LIEURS CLIVABLES NUCLÉOTIDIQUES ET LEURS UTILISATIONS
  申请人：SINGULAR GENOMICS SYSTEMS INC

  公开号：WO2020146397A1

  公开（公告）日：2020-07-16

  Disclosed herein, inter alia, are compounds, compositions, and methods of use thereof for sequencing a nucleic acid.

  在此披露的内容包括化合物、组合物以及它们的使用方法，用于测序核酸。
• Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
  申请人：——

  公开号：US20030109584A1

  公开（公告）日：2003-06-12

  Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, and some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. The aforementioned active substances may be destabilized by the environmental factors, their degradation may also be accelerated by interactions with other pharmaceutical ingredients, such as fillers, binders, lubricants, glidants and disintegrating agents, therefore the pharmaceutical ingredients and the process for preparation of the pharmaceutical formulation should be meticulously chosen to avoid the aforementioned undesired interactions and reactions. The present invention relates to a HMG-CoA reductase inhibitor which is stabilized by forming a homogeneous composition with a buffering substance or a basifying substance. This homogeneous composition is suitably used as the active substance in a pharmaceutical formulation for the treatment of hypercholesterolemia and hyperlipidemia.

  洛伐他汀、普拉伐他汀、辛伐他汀、麦伐他汀、阿托伐他汀以及它们的衍生物和类似物被称为HMG-CoA还原酶抑制剂，用作抗高胆固醇药物。它们大多数是通过利用不同物种的微生物进行发酵生产的，这些物种被鉴定为属于曲霉、红曲霉、诺卡氏菌、阿米科拉托普西斯、毛霉或青霉属，有些是通过对发酵产物进行化学合成方法处理得到的，或者它们是全化学合成的产物。上述活性物质可能会受到环境因素的破坏，它们的降解也可能会因与其他药物成分（如填料、粘结剂、润滑剂、滑石和分散剂）的相互作用而加速，因此应该精心选择药物成分和药物配方制备过程，以避免上述不良的相互作用和反应。本发明涉及一种通过与缓冲物质或碱化物质形成均匀组合而稳定的HMG-CoA还原酶抑制剂。这种均匀组合适用作为药物配方中的活性物质，用于治疗高胆固醇血症和高脂血症。
• Isolation of nucleic acids
  申请人：——

  公开号：US20010018513A1

  公开（公告）日：2001-08-30

  A method for extracting nucleic acids from a biological material such as blood comprises contacting the mixture with a material at a pH such that the material is positively charged and will bind negatively charged nucleic acids and then eluting the nucleic acids at a pH when the said materials possess a neutral or negative charge to release the nucleic acids. The nucleic acids can be removed under mildly alkaline conditions to the maintain integrity of the nucleic acids and to allow retrieval of the nucleic acids in reagents that are immediately compatible with either storage or analytical testing.

  一种从生物材料（如血液）中提取核酸的方法，包括将混合物与具有正电荷的材料接触，以结合负电荷的核酸，然后在材料具有中性或负电荷的pH下洗脱核酸。可以在温和碱性条件下去除核酸，以维持核酸的完整性，并允许在与存储或分析测试立即兼容的试剂中检索核酸。